185 related articles for article (PubMed ID: 38300970)
21. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines.
Welsh C; Day R; McGurk C; Masters JR; Wood RD; Köberle B
Int J Cancer; 2004 Jun; 110(3):352-61. PubMed ID: 15095299
[TBL] [Abstract][Full Text] [Related]
22. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of nucleotide excision repair by anti-XPA monoclonal antibodies which interfere with binding to RPA, ERCC1, and TFIIH.
Saijo M; Matsuda T; Kuraoka I; Tanaka K
Biochem Biophys Res Commun; 2004 Sep; 321(4):815-22. PubMed ID: 15358100
[TBL] [Abstract][Full Text] [Related]
24. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
[TBL] [Abstract][Full Text] [Related]
25. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
[TBL] [Abstract][Full Text] [Related]
26. Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours.
Mendoza J; Martínez J; Hernández C; Pérez-Montiel D; Castro C; Fabián-Morales E; Santibáñez M; González-Barrios R; Díaz-Chávez J; Andonegui MA; Reynoso N; Oñate LF; Jiménez MA; Núñez M; Dyer R; Herrera LA
Br J Cancer; 2013 Jul; 109(1):68-75. PubMed ID: 23807173
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the XPA and ssDNA-binding surfaces on the central domain of human ERCC1 reveals evidence for subfunctionalization.
Tripsianes K; Folkers GE; Zheng C; Das D; Grinstead JS; Kaptein R; Boelens R
Nucleic Acids Res; 2007; 35(17):5789-98. PubMed ID: 17720715
[TBL] [Abstract][Full Text] [Related]
28. Sequential binding of DNA repair proteins RPA and ERCC1 to XPA in vitro.
Saijo M; Kuraoka I; Masutani C; Hanaoka F; Tanaka K
Nucleic Acids Res; 1996 Dec; 24(23):4719-24. PubMed ID: 8972858
[TBL] [Abstract][Full Text] [Related]
29. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein-protein interaction.
Gentile F; Elmenoufy AH; Ciniero G; Jay D; Karimi-Busheri F; Barakat KH; Weinfeld M; West FG; Tuszynski JA
Chem Biol Drug Des; 2020 Apr; 95(4):460-471. PubMed ID: 31891209
[TBL] [Abstract][Full Text] [Related]
30. Nucleotide excision repair by mutant xeroderma pigmentosum group A (XPA) proteins with deficiency in interaction with RPA.
Saijo M; Takedachi A; Tanaka K
J Biol Chem; 2011 Feb; 286(7):5476-83. PubMed ID: 21148310
[TBL] [Abstract][Full Text] [Related]
31. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin.
Goldberg Z; Evans J; Birrell G; Brown JM
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):175-82. PubMed ID: 11163512
[TBL] [Abstract][Full Text] [Related]
32. Multiple DNA binding domains mediate the function of the ERCC1-XPF protein in nucleotide excision repair.
Su Y; Orelli B; Madireddy A; Niedernhofer LJ; Schärer OD
J Biol Chem; 2012 Jun; 287(26):21846-55. PubMed ID: 22547097
[TBL] [Abstract][Full Text] [Related]
33. Computational Characterization of Small Molecules Binding to the Human XPF Active Site and Virtual Screening to Identify Potential New DNA Repair Inhibitors Targeting the ERCC1-XPF Endonuclease.
Gentile F; Barakat KH; Tuszynski JA
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29710850
[TBL] [Abstract][Full Text] [Related]
34. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
[TBL] [Abstract][Full Text] [Related]
35. The role of conformational selection in the molecular recognition of the wild type and mutants XPA67-80 peptides by ERCC1.
Fadda E
Proteins; 2015 Jul; 83(7):1341-51. PubMed ID: 25973722
[TBL] [Abstract][Full Text] [Related]
36. Mutations in XPA that prevent association with ERCC1 are defective in nucleotide excision repair.
Li L; Peterson CA; Lu X; Legerski RJ
Mol Cell Biol; 1995 Apr; 15(4):1993-8. PubMed ID: 7891694
[TBL] [Abstract][Full Text] [Related]
37. Analysis of DNA binding by human factor xeroderma pigmentosum complementation group A (XPA) provides insight into its interactions with nucleotide excision repair substrates.
Sugitani N; Voehler MW; Roh MS; Topolska-Woś AM; Chazin WJ
J Biol Chem; 2017 Oct; 292(41):16847-16857. PubMed ID: 28860187
[TBL] [Abstract][Full Text] [Related]
38. Polymorphisms of nucleotide-excision repair genes may contribute to sperm DNA fragmentation and male infertility.
Gu A; Ji G; Zhou Y; Long Y; Shi X; Fu G; Wang S; Song L; Wang X
Reprod Biomed Online; 2010 Nov; 21(5):602-9. PubMed ID: 20864414
[TBL] [Abstract][Full Text] [Related]
39. Identification of novel small molecule inhibitors of the XPA protein using in silico based screening.
Neher TM; Shuck SC; Liu JY; Zhang JT; Turchi JJ
ACS Chem Biol; 2010 Oct; 5(10):953-65. PubMed ID: 20662484
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
Kudo K; Gavin E; Das S; Amable L; Shevde LA; Reed E
Oncogene; 2012 Nov; 31(44):4718-24. PubMed ID: 22266871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
